Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 5
1995 1
1999 2
2000 2
2002 1
2003 4
2004 5
2005 10
2006 23
2007 11
2008 25
2009 24
2010 28
2011 42
2012 47
2013 51
2014 85
2015 77
2016 106
2017 124
2018 135
2019 152
2020 159
2021 142
2022 154
2023 115
2024 46

Text availability

Article attribute

Article type

Publication date

Search Results

1,376 results

Results by year

Filters applied: . Clear all
Page 1
Cardiovascular Safety of Febuxostat or Allopurinol in Patients with Gout.
White WB, Saag KG, Becker MA, Borer JS, Gorelick PB, Whelton A, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. White WB, et al. N Engl J Med. 2018 Mar 29;378(13):1200-1210. doi: 10.1056/NEJMoa1710895. Epub 2018 Mar 12. N Engl J Med. 2018. PMID: 29527974 Free article. Clinical Trial.
RESULTS: In total, 6190 patients underwent randomization, received febuxostat or allopurinol, and were followed for a median of 32 months (maximum, 85 months). ...CONCLUSIONS: In patients with gout and major cardiovascular coexisting conditions, febuxostat was nonin …
RESULTS: In total, 6190 patients underwent randomization, received febuxostat or allopurinol, and were followed for a median of 32 mo …
Evaluation of the Relationship Between Serum Urate Levels, Clinical Manifestations of Gout, and Death From Cardiovascular Causes in Patients Receiving Febuxostat or Allopurinol in an Outcomes Trial.
Saag KG, Becker MA, White WB, Whelton A, Borer JS, Gorelick PB, Hunt B, Castillo M, Gunawardhana L; CARES Investigators. Saag KG, et al. Arthritis Rheumatol. 2022 Sep;74(9):1593-1601. doi: 10.1002/art.42160. Epub 2022 Aug 5. Arthritis Rheumatol. 2022. PMID: 35536764 Free PMC article. Clinical Trial.
OBJECTIVE: To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) causes after treatment with febuxostat or allopurinol in patients with gout from the Cardiovascular Safety of Febuxostat or Al …
OBJECTIVE: To investigate whether serum urate levels, number of gout flares, and tophi burden are related to death from cardiovascular (CV) …
Long-term cardiovascular safety of febuxostat compared with allopurinol in patients with gout (FAST): a multicentre, prospective, randomised, open-label, non-inferiority trial.
Mackenzie IS, Ford I, Nuki G, Hallas J, Hawkey CJ, Webster J, Ralston SH, Walters M, Robertson M, De Caterina R, Findlay E, Perez-Ruiz F, McMurray JJV, MacDonald TM; FAST Study Group. Mackenzie IS, et al. Lancet. 2020 Nov 28;396(10264):1745-1757. doi: 10.1016/S0140-6736(20)32234-0. Epub 2020 Nov 9. Lancet. 2020. PMID: 33181081 Clinical Trial.
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safe …
BACKGROUND: Febuxostat and allopurinol are urate-lowering therapies used to treat patients with gout. Following concerns about the ca …
Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: A systematic and meta-analysis.
Gao L, Wang B, Pan Y, Lu Y, Cheng R. Gao L, et al. Clin Cardiol. 2021 Jul;44(7):907-916. doi: 10.1002/clc.23643. Epub 2021 May 20. Clin Cardiol. 2021. PMID: 34013998 Free PMC article. Review.
The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. ...This meta-analysis adds new evidence regarding the cardiovascular safety of febuxostat in patients. Initiation of febuxostat in patients was not as …
The cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout remains equivocal. ...This meta-analysis ad …
Febuxostat Therapy for Patients With Stage 3 CKD and Asymptomatic Hyperuricemia: A Randomized Trial.
Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, Ito S, Yamamoto T, Tomino Y, Ohno I, Shibagaki Y, Iimuro S, Imai N, Kuwabara M, Hayakawa H, Ohtsu H, Ohashi Y; FEATHER Study Investigators. Kimura K, et al. Am J Kidney Dis. 2018 Dec;72(6):798-810. doi: 10.1053/j.ajkd.2018.06.028. Epub 2018 Sep 1. Am J Kidney Dis. 2018. PMID: 30177485 Free article. Clinical Trial.
RESULTS: Of 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in the analysis. ...The incidence of gouty arthritis was significantly lower (P=0.007) in the febuxostat group (0.91%) than in the placeb …
RESULTS: Of 443 patients who were randomly assigned, 219 and 222 assigned to febuxostat and placebo, respectively, were included in t …
The role of febuxostat in gout.
Bardin T, Richette P. Bardin T, et al. Curr Opin Rheumatol. 2019 Mar;31(2):152-158. doi: 10.1097/BOR.0000000000000573. Curr Opin Rheumatol. 2019. PMID: 30601228 Review.
PURPOSE OF REVIEW: Concerns about the cardiovascular safety of febuxostat lead to reconsideration of the place of febuxostat in the management of gout. RECENT FINDINGS: The CARES trial is a randomized controlled trial mandated by the FDA to compare the cardiovascula …
PURPOSE OF REVIEW: Concerns about the cardiovascular safety of febuxostat lead to reconsideration of the place of febuxostat i …
Febuxostat and renal outcomes: post-hoc analysis of a randomized trial.
Kohagura K, Kojima S, Uchiyama K, Yokota N, Tokutake E, Wakasa Y, Hiramitsu S, Waki M, Jinnouchi H, Kakuda H, Hayashi T, Kawai N, Sugawara M, Mori H, Tsujita K, Matsui K, Hisatome I, Ohya Y, Kimura K, Saito Y, Ogawa H; Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Kohagura K, et al. Hypertens Res. 2023 Jun;46(6):1417-1422. doi: 10.1038/s41440-023-01198-x. Epub 2023 Feb 7. Hypertens Res. 2023. PMID: 36750608 Clinical Trial.
The relative risk of developing or worsening macroalbuminuria was 56% lower in the febuxostat group (hazard ratio, 0.44; 95% CI, 0.24-0.82; P = 0.0098). ...In patients with asymptomatic hyperuricemia without gout, febuxostat reduces the risk of development or worsen …
The relative risk of developing or worsening macroalbuminuria was 56% lower in the febuxostat group (hazard ratio, 0.44; 95% CI, 0.24 …
2020 American College of Rheumatology Guideline for the Management of Gout.
FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. FitzGerald JD, et al. Arthritis Rheumatol. 2020 Jun;72(6):879-895. doi: 10.1002/art.41247. Epub 2020 May 11. Arthritis Rheumatol. 2020. PMID: 32390306 Free article.
Strong recommendations included initiation of ULT for all patients with tophaceous gout, radiographic damage due to gout, or frequent gout flares; allopurinol as the preferred first-line ULT, including for those with moderate-to-severe chronic kidney disease (CKD; stage >3); u …
Strong recommendations included initiation of ULT for all patients with tophaceous gout, radiographic damage due to gout, or frequent gout f …
Update on gout management: what is old and what is new.
Afinogenova Y, Danve A, Neogi T. Afinogenova Y, et al. Curr Opin Rheumatol. 2022 Mar 1;34(2):118-124. doi: 10.1097/BOR.0000000000000861. Curr Opin Rheumatol. 2022. PMID: 34907116 Free PMC article. Review.
Trial data have provided new insights regarding cardiovascular risk with febuxostat. Several new drug therapies are being tested for both urate-lowering efficacy and gout flare management. ...
Trial data have provided new insights regarding cardiovascular risk with febuxostat. Several new drug therapies are being tested for …
Risk of Erectile Dysfunction in Male Patients with Gout Treated with Febuxostat or Allopurinol: A Propensity Score-Matched Cohort Study.
Tong Q, Du Y, Cui R, Chen M, Wang SI, Wei JC, Dai SM. Tong Q, et al. Drugs. 2022 Dec;82(18):1717-1726. doi: 10.1007/s40265-022-01816-x. Epub 2022 Dec 7. Drugs. 2022. PMID: 36479686
RESULTS: We identified 679,862 patients with gout among 107,517,445 patients in the database. Of these patients, 24,000 were treated with febuxostat and 299,726 with allopurinol. After propensity matching, 9075 patients receiving febuxostat without allopurinol (f …
RESULTS: We identified 679,862 patients with gout among 107,517,445 patients in the database. Of these patients, 24,000 were treated with …
1,376 results